---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276930"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:54:04.953167+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia Q3 Auryxia revenue up 14.9% to $42.2M; files FDA dispute for vadadustat

## Summary
- Net product revenue $42.2M (+14.9% YoY); total revenue $49.0M vs $48.8M YoY.
- Net loss $51.9M vs $59.5M YoY; cash $144.8M, sufficient for at least 12 months.
- Filed Formal Dispute Resolution Request with FDA over vadadustat CRL; response expected by end-2022.
- Retired $33M of Pharmakon debt; 2022 Auryxia revenue guidance reaffirmed at $170-175M.
- Assumed EU marketing application for vadadustat; EMA decision expected Q1 2023.

## SEC filing metadata
- accession: 0001193125-22-276930
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/0001193125-22-276930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/d402663d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276930
- JSON: https://secwatch.observer/filing/0001193125-22-276930.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276930.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $49.0 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $49.0 million
  - Result: reported results
  source text: net price per pill puts us in a position to affirm our 2022 net product revenue guidance for Auryxia of $170 - $175 million.” Financial Results • Revenues: Total revenue was $49.0 million in the third quarter of 2022 compared to $48.8 million for the third quarter of 2021. • Net product revenue was $42.2 million in the third quarter of 2022 compared to $36.8
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/0001193125-22-276930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.